Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) saw an uptick in trading volume on Monday . 8,005,833 shares traded hands during trading, an increase of 3% from the previous session's volume of 7,745,387 shares.The stock last traded at $3.1150 and had previously closed at $3.11.
Analyst Ratings Changes
A number of equities research analysts have issued reports on the stock. Wall Street Zen raised shares of Esperion Therapeutics from a "hold" rating to a "buy" rating in a report on Saturday, March 14th. Needham & Company LLC increased their price objective on shares of Esperion Therapeutics from $4.00 to $5.00 and gave the company a "buy" rating in a report on Tuesday, March 3rd. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Esperion Therapeutics in a report on Tuesday, April 21st. Cantor Fitzgerald lowered shares of Esperion Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday. Finally, Citizens Jmp increased their price objective on shares of Esperion Therapeutics from $4.00 to $5.00 and gave the company a "market outperform" rating in a report on Friday, March 13th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $5.54.
View Our Latest Stock Report on Esperion Therapeutics
Esperion Therapeutics Stock Up 0.2%
The business's fifty day moving average is $2.55 and its two-hundred day moving average is $3.08. The stock has a market capitalization of $801.80 million, a PE ratio of -18.32, a price-to-earnings-growth ratio of 2.53 and a beta of 0.91.
Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last posted its earnings results on Tuesday, March 10th. The biopharmaceutical company reported $0.22 earnings per share for the quarter, missing analysts' consensus estimates of $0.23 by ($0.01). The company had revenue of $168.45 million for the quarter, compared to analysts' expectations of $165.12 million. Sell-side analysts expect that Esperion Therapeutics, Inc. will post 0.05 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of the business. Hsbc Holdings PLC grew its holdings in shares of Esperion Therapeutics by 160.1% in the first quarter. Hsbc Holdings PLC now owns 48,141 shares of the biopharmaceutical company's stock valued at $132,000 after purchasing an additional 29,631 shares in the last quarter. AIGH Capital Management LLC grew its holdings in shares of Esperion Therapeutics by 10.0% in the first quarter. AIGH Capital Management LLC now owns 4,400,000 shares of the biopharmaceutical company's stock valued at $12,056,000 after purchasing an additional 400,000 shares in the last quarter. Wasatch Advisors LP grew its holdings in shares of Esperion Therapeutics by 66.9% in the first quarter. Wasatch Advisors LP now owns 15,768,897 shares of the biopharmaceutical company's stock valued at $43,207,000 after purchasing an additional 6,323,138 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of Esperion Therapeutics by 151.0% in the first quarter. SG Americas Securities LLC now owns 127,983 shares of the biopharmaceutical company's stock valued at $351,000 after purchasing an additional 76,986 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its holdings in shares of Esperion Therapeutics by 17.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 36,744 shares of the biopharmaceutical company's stock valued at $136,000 after purchasing an additional 5,492 shares in the last quarter. 47.39% of the stock is owned by hedge funds and other institutional investors.
About Esperion Therapeutics
(
Get Free Report)
Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company's research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.
The company's lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Esperion Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Esperion Therapeutics wasn't on the list.
While Esperion Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
